Retatrutide vs Tirzepatide
Receptor profiles, mechanism differences, and research considerations.
| Property | Retatrutide | Tirzepatide |
|---|---|---|
| Receptor targets | GLP-1, GIP, Glucagon | GLP-1, GIP |
| Classification | Triple agonist | Dual agonist (twincretin) |
| Molecular weight | ~4765 g/mol | ~4813 g/mol |
| Research status | Phase II/III investigation | Approved (clinical); research use |
| Glucagon receptor activity | Yes | No |
| Half-life (approx.) | ~7 days | ~5 days |
Mechanism Overview
Tirzepatide
Tirzepatide is a dual agonist that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. The GIP receptor activation is a key differentiator from earlier GLP-1 single agonists. Research on tirzepatide explores how simultaneous GIP and GLP-1 activation affects insulin secretion, glucagon suppression, and adipose tissue signaling relative to GLP-1 monotherapy models.
Retatrutide
Retatrutide adds glucagon receptor agonism to the GIP/GLP-1 dual agonist profile. The glucagon receptor component is hypothesized to contribute to increased energy expenditure — a mechanism not present in GLP-1 or dual GIP/GLP-1 agonists. Research models investigate how this triple receptor profile affects hepatic metabolism, thermogenesis, and overall energy homeostasis compared to dual agonist approaches.
Research Considerations
Both compounds are relevant to metabolic research but model different receptor engagement profiles. Researchers studying GLP-1 pathway biology who want to isolate GIP contributions may prefer tirzepatide. Researchers investigating the role of glucagon receptor co-activation in metabolic outcomes may find retatrutide's triple agonist profile more relevant to their research questions.
Neither compound is approved for human use outside of regulated clinical contexts. Both are available from OPSEK Labs for laboratory research purposes only with full lot-specific documentation.